Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations

European Journal of Cancer

Volumn 43, Issue 1, 2007, Pages 46-52

  Thuerlimann, Beat ^a   Koeberle, Dieter ^a   Senn, Hans Joerg ^b  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b Centre of Tumour Detection   (Switzerland)

Author keywords

Adjuvant; Aromatase inhibitor; Breast cancer; Guidelines; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; TAMOXIFEN; TRASTUZUMAB; ZOLEDRONIC ACID;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; STANDARD; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FORECASTING; GUIDELINE ADHERENCE; HUMANS; POSTMENOPAUSE; PRACTICE GUIDELINES;

EID: 33846179352     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.09.003     Document Type: Article

References (34)

1. Davis D., O'Brien M.A., Freemantle N., et al. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?. JAMA 282 (1999) 867-874
2. Pestalozzi B.C., Luporsi-Gely E., Jost L.M., and Bergh J. ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 16 Suppl 1 (2005) i7-i9
3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology - version 2.2006. 12-5-05 ©2005 National Comprehensive Cancer Network, Inc.
4. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629 Epub 15 Nov 2004
5. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687
7. Piccart M.J., de Valeriola D., Dal Lago L., et al. Adjuvant chemotherapy in 2005: standards and beyond. Breast 14 (2005) 439-445 Epub 26 Sep 2005
8. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
9. Slamon D., Eiermann W., Robert N., et al. on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 Suppl 1 (2005) S5 Abstract 1
10. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology - version 1.2005. 02-10-05 ©2005 National Comprehensive Cancer Network, Inc.
12. Pritchard K. Adjuvant endocrine therapies for pre/perimenopausal women. Breast 14 Suppl 1 (2005) S9 Abstract S23
13. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
14. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
15. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 88 (1996) 1834-1839
16. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 21 (2003) 2597-2599
17. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
18. Ingle J.N., Tu D., Pater J.L., Martino S., et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. (2006) Epub ahead of print 16 Mar
19. Thürlimann B., Keshaviah A., Coates A.S., et al., Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
20. McArthur H.L., Olivotto I., Gelmon K.A., et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res Treat 94 Suppl 1 (2005) S124 Abstract 3001
21. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 (2005) 7512-7517
22. Viale G., Regan M., Dell'Orto P., et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 94 Suppl 1 (2005) S13 Abstract 44
23. Oestreicher N., Ramsey S.D., Linden H.M., et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?. Genet Med 7 (2005) 380-389
24. Brufsky A., Harker G., Beck T., et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial. J Clin Oncol 23 Suppl 16 (2005) 12S Abstract 533
25. Howell A., and Cuzick J. Vascular effects of aromatase inhibitors: Data from clinical trials. J Steroid Biochem Mol Biol 95 1-5 (2005) 143-149 Erratum in: J Steroid Biochem Mol Biol 2006; 98(2-3):180.
26. Goss P.E., and Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res 10 1 Pt 2 (2004) 372S-379S
27. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23 (2005) 1636-1643
28. De Boer R, Burris H, Monnier A et al., on behalf of the H2H Trial Steering Committee. The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. [Abstract]. American Society of Clinical Oncology 2006 [In press].
29. Verma S, Trudeau M. Canadian oncologists attitudes towards guideline development and outcomes of clinical trials based on results of the ATAC trial. Proceedings of the 26th Annual San Antonio Breast Cancer Symposium, December 3-6; 2003. Abstract 657.
30. Palazzi M., De Tomasi D., D'Affronto C., et al. Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice? Results of a population-based study on 1547 patients. Tumori 88 (2002) 503-506
31. Roila F., Ballatori E., Patoia L., et al., Drug Utilization Review Team in Oncology. Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Ann Oncol 14 (2003) 843-848
32. Goldhirsch A., Glick J.H., Gelber R.D., and Senn H.J. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90 (1998) 1601-1608
33. Hebert-Croteau N., Brisson J., Latreille J., et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 22 (2004) 3685-3693 Epub ahead of print 2 Aug 2004
34. Bloom B.S., de Pouvourville N., Chatre S., et al. Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer 90 (2004) 26-30